Context to Participate in Upcoming Investor Conferences in April
Philadelphia, PA, March 19, 2019 – Context Therapeutics, a clinical-stage biotechnology company focused on hormone driven cancers, today announced it will present at the following upcoming investor conferences.
Needham and Company 18th Annual Health Care Conference in New York City on Tuesday, April 9, 2019 at 2:30 p.m. ET.
About Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor, an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) breast, endometrial, and ovarian cancers. In addition, Context is advancing CTX-30916, a preclinical progesterone receptor antagonist. For more information on Context, visit www.contexttherapeutics.com.